Glucocorticoid-induced Osteoporosis and Osteonecrosis

Overview

Journal Endocrinol Metab Clin North Am

Publisher Elsevier

Specialty Endocrinology

Date 2012 Aug 11

PMID 22877431

Citations 146

Authors

Robert S Weinstein

Affiliations

Soon will be listed here.

Abstract

Glucocorticoid administration is the most common cause of secondary osteoporosis and the leading cause of nontraumatic osteonecrosis. In patients receiving long-term therapy, glucocorticoids induce fractures in 30% to 50% and osteonecrosis in 9% to 40%. This article reviews glucocorticoid-induced osteoporosis and osteonecrosis, addressing the risk factors, pathogenesis, evaluation, treatment, and uncertainties in the clinical management of these disorders.

Citing Articles

The role of the PKCζ/JNK signaling pathway in regulating the development of femoral head necrosis.

Hu M, Li C, Sun Q, Hu B, Yang J, Wang X Braz J Med Biol Res. 2025; 58:e13771.

PMID: 40053032 PMC: 11884774. DOI: 10.1590/1414-431X2025e13771.

The Role of Cortisol and Dehydroepiandrosterone in Obesity, Pain, and Aging.

Erceg N, Micic M, Forouzan E, Knezevic N Diseases. 2025; 13(2).

PMID: 39997049 PMC: 11854441. DOI: 10.3390/diseases13020042.

Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis.

Grygorieva N, Kovalenko V, korzh M, Tronko M, Golovach I, Dedukh N Arch Osteoporos. 2025; 20(1):31.

PMID: 39992470 DOI: 10.1007/s11657-025-01512-9.

miR-125b differentially impacts mineralization in dexamethasone and calcium-treated human mesenchymal stem cells.

Joris V, Balmayor E, van Griensven M Mol Ther Nucleic Acids. 2025; 36(1):102446.

PMID: 39897583 PMC: 11787018. DOI: 10.1016/j.omtn.2024.102446.

Eucommia ulmoides Oliver polysaccharide alleviates glucocorticoid-induced osteoporosis by stimulating bone formation via ERK/BMP-2/SMAD signaling.

Song J, Zhang Y, Jin X, Zhu Y, Li Y, Hu M Sci Rep. 2024; 14(1):29647.

PMID: 39609585 PMC: 11604974. DOI: 10.1038/s41598-024-80859-4.

References

Adachi J, Saag K, Delmas P, Liberman U, Emkey R, Seeman E . Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001; 44(1):202-11. DOI: 10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W. View

Hansen K, Wilson H, Zapalowski C, Fink H, Minisola S, Adler R . Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res. 2011; 26(9):1989-96. DOI: 10.1002/jbmr.362. View

Russcher H, Smit P, van den Akker E, van Rossum E, Brinkmann A, de Jong F . Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression. J Clin Endocrinol Metab. 2005; 90(10):5804-10. DOI: 10.1210/jc.2005-0646. View

Weinstein R, Nicholas R, Manolagas S . Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000; 85(8):2907-12. DOI: 10.1210/jcem.85.8.6714. View

Weinstein R, Jia D, Powers C, Stewart S, Jilka R, Parfitt A . The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology. 2004; 145(4):1980-7. DOI: 10.1210/en.2003-1133. View

Weinstein R, Jilka R, Parfitt A, Manolagas S . Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102(2):274-82. PMC: 508885. DOI: 10.1172/JCI2799. View

Black D, Kelly M, Genant H, Palermo L, Eastell R, Bucci-Rechtweg C . Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362(19):1761-71. DOI: 10.1056/NEJMoa1001086. View

Emkey R, Delmas P, Goemaere S, Liberman U, Poubelle P, Daifotis A . Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum. 2003; 48(4):1102-8. DOI: 10.1002/art.10861. View

Miller P . Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008; 6(1):12-6. DOI: 10.1007/s11914-008-0003-y. View

10.

Syed M, Patel N, Jan S, Shaikh A, Grunden B, Morar K . Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. AJNR Am J Neuroradiol. 2006; 27(9):1938-43. PMC: 7977917. View

11.

Freyberg R, TRAEGER C, Patterson M, SQUIRES W, Adams C . Problems of prolonged cortisone treatment for rheumatoid arthritis; further investigations. J Am Med Assoc. 1951; 147(16):1538-43. DOI: 10.1001/jama.1951.03670330030008. View

12.

Weinstein R . Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures?. Nat Clin Pract Endocrinol Metab. 2007; 3(2):86-7. PMC: 2040103. DOI: 10.1038/ncpendmet0372. View

13.

Xiong J, Onal M, Jilka R, Weinstein R, Manolagas S, OBrien C . Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17(10):1235-41. PMC: 3192296. DOI: 10.1038/nm.2448. View

14.

Weinstein R, Wan C, Liu Q, Wang Y, Almeida M, OBrien C . Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010; 9(2):147-61. PMC: 2858771. DOI: 10.1111/j.1474-9726.2009.00545.x. View

15.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

16.

Weinstein R, Roberson P, Manolagas S . Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009; 360(1):53-62. PMC: 2866022. DOI: 10.1056/NEJMoa0802633. View

17.

Hofbauer L, Gori F, Riggs B, Lacey D, Dunstan C, Spelsberg T . Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology. 1999; 140(10):4382-9. DOI: 10.1210/endo.140.10.7034. View

18.

Plotkin L, Weinstein R, Parfitt A, Roberson P, Manolagas S, Bellido T . Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999; 104(10):1363-74. PMC: 409837. DOI: 10.1172/JCI6800. View

19.

Tauchmanova L, Pivonello R, Di Somma C, Rossi R, De Martino M, Camera L . Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab. 2006; 91(5):1779-84. DOI: 10.1210/jc.2005-0582. View

20.

Saag K, Shane E, Boonen S, Marin F, Donley D, Taylor K . Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-39. DOI: 10.1056/NEJMoa071408. View